24/04/2019 16:20:00

Exercise of Restricted Stock Units

Summit Therapeutics plc 

(‘Summit’ or the ’Company’)

Exercise of Restricted Stock Units and Total Voting Rights

Oxford, UK, and Cambridge, MA, US, 24 April 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM) announces the exercise by certain Non-Executive Directors of restricted stock units (‘RSUs’) that entitled the holder to subscribe for an ordinary share of one penny nominal value at a subscription price of one penny per ordinary share.  The RSUs were granted under the Company’s 2017 Remuneration Policy and were eligible for exercise for a limited time after completion of a vesting period of one year. Details of the exercise of the RSUs, all of which took place on 23 April 2019, and which have been duly notified to the Company, are summarised below.

DirectorPositionRSU’s Exercised
Frank ArmstrongNon-Executive Chairman36,585
Valerie AndrewsNon-Executive Director17,073
Dave WurzerNon-Executive Director17,073
Total 70,731

Following the exercise of the RSUs, the shareholdings of all the Non-Executive Directors are as follows:


(ordinary shares)

% of Issued Share Capital
Frank ArmstrongNon-Executive Chairman158,789*0.1%
Leopoldo ZambelettiNon-Executive Director15,9790.01%
Valerie AndrewsNon-Executive Director66,1960.04%
Dave WurzerNon-Executive Director63,1960.04%
Total 304,1600.19%

* Includes shares held by persons closely associated with the director

The Company also announces the exercise of a further 34,146 RSUs by former Non-Executive Directors of Summit. 

Application has been made to the London Stock Exchange for the admission of 104,877 ordinary shares to trading on AIM and it is expected that admission will become effective and that dealings will commence at 8.00 a.m. on or around 30 April 2019.

Total Voting Rights

Following the exercise of these RSUs, the total number of ordinary shares following admission will be 160,494,758 with each ordinary share carrying the right to one vote. The Company has no shares in Treasury; therefore following admission the total number of voting rights in Summit will be 160,494,758. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify an interest in, or change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

About Summit Therapeutics

Summit Therapeutics is a leader in antibiotic innovation. Our new mechanism antibiotics are designed to become the new standards of care for the benefit of patients and create value for payors and healthcare providers. We are currently developing new mechanism antibiotics for infections caused by C. difficile,N. gonorrhoeae and ESKAPE pathogens and are using our proprietary Discuva Platform to expand our pipeline. For more information, visit www.summitplc.com and follow us on Twitter @summitplc.





Richard Pye (UK office)


+44 (0)1235 443 951
Michelle Avery (US office)


+1 617 225 4455




Cairn Financial Advisers LLP (Nominated Adviser)


+44 (0)20 7213 0880
Liam Murray / Tony Rawlinson






Notification of Transactions pursuant to Article 19(1) of Regulation (EU) No. 596/2014


Details of the persons discharging managerial responsibilities/person closely associated


  1. Frank Armstrong
  2. Valerie Andrews
  3. Dave Wurzer


Reason for the notification

a)Position / status

  1. Non-Executive Chairman
  2. Non-Executive Director
  3. Non-Executive Director

b)Initial notification / AmendmentInitial notification


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)NameSummit Therapeutics plc


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)Description of the financial instrument, type of instrumentOrdinary shares of 1 penny each
Identification codeGB00BN40HZ01
b)Nature of the transactionsExercise of restricted stock units (RSUs) to subscribe for ordinary shares of one penny nominal value
c)Price(s) and volume(s) 




(i)-(iii) 1p (exercise price)



  1. 36,585

(ii)-(iii) 17,073

d)Aggregated information


- Aggregated volume


- Price



70,731 ordinary shares


1 penny (exercise price)


e)Date of the transactions23 April 2019
f)Place of the transactionsOutside a trading venue


Summit Master_rgb_png.png

Related content
20 Jun - 
Summit to Present on Pipeline and Strategy for its New ..
19 Jun - 
Result of AGM
18 Jun - 
Increased BARDA Award and Option Exercise

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg


EuroInvestor: In Focus


EuroInvestor: In Focus


EuroInvestor: In Focus

Most read news

  • 24 hours
  • 48 hours
  • 1 week
ROHM's New Power Supply Monitoring IC with Built-In Self-Diagnostic Function that Supports Functional Safety
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sprint Corporation, Boston Scientific Corporation, Box, Inc. and Cloudera, Inc. and Encourages Investors to Contact the Firm
Equity Trustees appointed Authorised Corporate Director to the AllianceBernstein UK OEIC
Genocea Announces Pricing of $36,750,000 Public Offering of Common Stock
Atreca Announces Pricing of Initial Public Offering

Related stock quotes

Latest news

Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
21 June 2019 01:16:09
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190527.1 - EUROWEB1 - 2019-06-21 02:16:09 - 2019-06-21 01:16:09 - 1000 - Website: OKAY